Axitinib is approved to treat: Renal cell carcinoma (a type of kidney cancer) that is advanced. It is used in patients whose disease has not gotten better with other chemotherapy.
Please fill in the details about your medicine requirement on this form.
60/4, T&T House. Yusuf Sarai.
New Delhi:110016 India.
Axitinib (AG013736; trade name Inlyta) is a small molecule tyrosine kinase inhibitor developed by Pfizer. It has been shown to significantly inhibit growth of breast cancer in animal (xenograft) models and has shown partial responses in clinical trials with renal cell carcinoma (RCC) and several other tumour types. It has received approval for use as a treatment for renal cell carcinoma from US FDA (27 January 2012), EMA (13 September 2012), UK MHRA (3 September 2012) and Australian TGA (26 July 2012) .
Global Pharma Network can help you to provide access of Axitinib medications sold under the brand name for Kidney Cancer treatment by connecting Patients, Health Care Centers, Pharmacies and Retail Outlets with approved supplier, exporter and distributor of Generic drugs, innovator brands and biosimilar medicines from India. Call Mr. Tarun at +91 8744044044 for more details.
The Global Pharma Network is not an online pharmacy company but we help patient to connect with suppliers in the delivering of Kidney Cancer medications a pharmaceutical drug (prescription drug, prescription medication or prescription medicine) that legally requires a medical prescription to be dispensed in following countries as per the customer's prescribed medication and applicable regulatory approval.
International: Epclusa, Harvoni, Vosevi Indian Manaufacturer Brands: Hepcinat (Natco Pharma Ltd.) / Hepcvir (Cipla Limited) / Resof (Hetero Drugs Ltd ) / SoviHep (Zydus Cadila)
Global Pharma Network will help you in importing and exporting this medicine only upon the valid prescription of a licensed medical practitioner and other documents as required by the laws of the jurisdiction in which you are present. USA, UK, Russia, China, India, Nepal, Bhutan, Myanmar / Burma, Laos, Thailand, Cambodia, Hong Kong, Macau, Malaysia, Indonesia, Middle East, Japan, Philippines.